

CALENDAR YEAR 2014

TOP 25 DRUGS BY EXPENDITURE, all data FFS

DRUG NAME	Paid Amount*	Claim Count	Recipient Distinct Count	Quantity Dispensed	Days Supplied	Average Reimbursement Rate Per Unit**
ABILIFY	\$28,230,188.01	35,103	6,939	1,143,023	1,038,926	\$25.18
VYVANSE	\$22,231,939.92	111,847	20,158	3,353,175	3,344,296	\$6.51
INVEGA SUSTENNA	\$15,440,098.97	10,861	1,364	12,841	297,236	\$1,211.37
ADDERALL XR	\$13,202,578.83	59,806	9,846	1,856,727	1,787,861	\$6.86
FOCALIN XR	\$12,248,397.59	55,251	12,066	1,690,408	1,653,161	\$7.18
SOVALDI	\$11,903,249.75	433	151	12,124	12,124	\$983.84
PROAIR HFA	\$11,480,165.83	178,029	85,199	1,800,190	4,115,549	\$5.54
NASONEX	\$9,905,471.10	60,135	35,714	1,022,295	1,778,495	\$9.35
INTUNIV	\$9,776,347.36	36,688	7,015	1,106,035	1,083,502	\$8.84
LYRICA	\$8,550,757.13	31,096	5,908	2,064,021	915,237	\$4.12
METHYLPHENIDATE ER	\$8,289,064.10	54,876	9,919	1,748,617	1,640,619	\$4.65
PULMICORT	\$8,204,426.04	17,986	9,584	1,643,384	490,018	\$4.96
SYNAGIS	\$7,807,030.39	3,510	1,182	3,159	98,341	\$2,481.89
NOVOSEVEN RT	\$7,432,834.06	84	10	4,355,000	960	\$1.71
LANTUS SOLOSTAR	\$6,336,150.86	17,718	4,308	298,165	507,715	\$21.22
MAKENA	\$6,215,412.02	1,823	774	9,115	51,989	\$689.91
EXJADE	\$6,183,418.64	752	125	87,626	22,438	\$71.53
DULERA	\$6,037,062.74	25,614	9,444	331,319	733,147	\$18.06
KOGENATE FS	\$5,983,292.93	350	25	5,268,723	5,337	\$1.13
HUMALOG	\$5,958,880.31	17,426	3,758	296,517	480,951	\$20.18
TAMIFLU	\$5,670,799.57	33,777	32,723	2,215,968	198,657	\$2.48
FLOVENT HFA	\$5,388,597.24	30,733	13,730	355,244	894,984	\$14.62
ADVAIR DISKUS	\$4,749,505.52	16,809	6,325	1,008,033	501,785	\$4.66
MONTELUKAST SODIUM	\$4,629,583.81	160,482	69,315	6,499,676	6,500,487	\$0.47
LANTUS	\$4,618,821.88	14,974	2,981	222,670	405,552	\$20.58
HARVONI	\$756,161.76	24	24	672	672	\$1,125.00

*Prior to rebates, reported in total dollars

**Averaged over CY2014

-Number of total lives (all FFS) covered straight Medicaid: approx 1,031,000 average monthly eligibles for CY2014

-No supplemental rebate for Sovaldi or Harvoni; no special funding provisions

-Estimate of number of HCV patients: approx 6,200 recipients with a claim with a Hepatitis C diagnosis codes during the period July 2013 – December 2014